Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00989911 · ClinicalTrials.gov registry record · NA
Endothelin Blockade in Patients With Single Ventricle Physiology
A NA study, sponsored by University of California, Los Angeles.
- Completed
- Registry status
- NA
- Development phase
- 10
- Enrollment target
NCT00989911 is a NA study that has completed, run by University of California, Los Angeles. The registered enrollment target is 10 participants.
The verdict
NCT00989911, a NA study, has completed, sponsored by University of California, Los Angeles.
- COMPLETED
- Registry status
- NA
- Development phase
- 10 participants
- Enrollment target
Study Summary
Recent studies have shown beneficial effects of sildenafil in patients with single ventricle congenital heart disease. The purpose of this study is to determine whether Bosentan, a drug with similar effects, will have similar benefit in this patient population.
Interventions
- DRUG Bosentan
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10 participants |
| Start Date | 2010-05 |
| Est. Completion | 2013-03 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00989911
The ClinicalTrials.gov registry entry for NCT00989911 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 10 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of California, Los Angeles, which has 897 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Bosentan is the first listed.
NCT00989911 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00989911 about?
NCT00989911 is a clinical study titled "Endothelin Blockade in Patients With Single Ventricle Physiology". Recent studies have shown beneficial effects of sildenafil in patients with single ventricle congenital heart disease. The purpose of this study is to determine whether Bosentan, a drug with similar effects, will have similar benefit in this patient population.
What is the current status of trial NCT00989911?
This trial is currently completed. It is a NA study. The enrollment target is 10 participants. The study started on 2010-05. Estimated completion is 2013-03.
What interventions are being tested in trial NCT00989911?
The interventions under investigation include: Bosentan (DRUG).
Who is sponsoring clinical trial NCT00989911?
This trial is sponsored by University of California, Los Angeles, which has 897 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.